Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Unique microRNAs appear at different times during the course of a delayed-type hypersensitivity reaction in human skin

Research output: Contribution to journalJournal articleResearchpeer-review

DOI

  1. Carbonic anhydrases in human keratinocytes and their regulation by all-trans retinoic acid and 1α,25-dihydroxyvitamin D3

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. The role of skin barrier in occupational contact dermatitis

    Research output: Contribution to journalReviewResearchpeer-review

  3. Red tattoos, ultraviolet radiation and skin cancer in mice

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Spatially and cell-type resolved quantitative proteomic atlas of healthy human skin

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Repeated treatments with ingenol mebutate for prophylaxis of UV-induced squamous cell carcinoma in hairless mice

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Repeated Treatments with Ingenol Mebutate Prevents Progression of UV-Induced Photodamage in Hairless Mice

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Ablative fractional laser alters biodistribution of ingenol mebutate in the skin

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

Diphencyprone (DPCP) is a hapten that induces delayed-type hypersensitivity (DTH) reactions. MicroRNAs (miRNAs) are short non-coding RNAs that negatively regulate gene expression and have been implicated in various inflammatory skin diseases, but their role in DTH reactions is not well understood. We generated global miRNA expression profiles (using next-generation sequencing) of DPCP reactions in skin of seven healthy volunteers at 3, 14 and 120 days after challenge. Compared to placebo-treated sites, DPCP-challenged skin at 3 days (peak inflammation) had 127 miRNAs significantly deregulated. At 14 days (during resolution of inflammation), 43 miRNAs were deregulated and, at 120 days (when inflammation had completely resolved), six miRNAs were upregulated. While some miRNAs have been observed in psoriasis or atopic dermatitis, most of the deregulated miRNAs have not yet been studied in the context of skin biology or immunology. Across the three time points studied, many but not all miRNAs were uniquely expressed. As various miRNAs may influence T cell activation, this may indicate that the miRNAs exclusively expressed at different time points function to promote or resolve skin inflammation, and therefore, may inform on the paradoxical ability of DPCP to treat both autoimmune conditions (alopecia areata) and conditions of ineffective immunity (melanoma).

Original languageEnglish
JournalExperimental Dermatology
Volume24
Issue number12
Pages (from-to)953-7
Number of pages5
ISSN0906-6705
DOIs
Publication statusPublished - Dec 2015

ID: 46308428